微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 20.53% | -32.08% | -6.25% | 133/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 21.9% | -39.16% | -1.23% | 132/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 22.18% | -41.51% | -23.11% | 130/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 28.84% | -28.21% | -4.6% | 122/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 30.23% | -25.81% | -16.03% | 120/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 36% | -8.63% | -5.05% | 106/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 37.92% | 17.68% | -5.62% | 101/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 40.17% | 39.11% | -1.41% | 104/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 40.75% | 38.11% | 3.41% | 102/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 39.4% | 36.72% | 22.3% | 105/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 32.22% | 8.26% | 11.58% | 115/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 28.88% | -14.92% | -2.12% | 121/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 29.5% | -18.25% | 2.37% | 113/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 28.82% | -22.33% | -3.17% | 121/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 29.76% | 2% | -12.31% | 115/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 33.94% | -31.64% | -5.94% | 120/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 36.09% | 2% | -2.74% | 102/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 37.11% | -25.82% | -25.26% | 109/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 49.65% | -3.84% | -0.75% | 81/159 | -145.9% | 艾力斯 | 99.4% | 行业排名> |
| 2020-06-30 | 50.02% | 2% | -3.12% | 71/159 | 54.11% | 首药控股 | 99.94% | 行业排名> |
| 2019-12-31 | 51.63% | 20.54% | 20.54% | 72/159 | -1222.98% | 泽璟制药 | 99.96% | 行业排名> |
| 2018-12-31 | 42.83% | 55.81% | 55.81% | 86/159 | -208.09% | 微芯生物 | 95.14% | 行业排名> |
| 2017-12-31 | 27.49% | 2% | 2% | 108/159 | 52.32% | 多瑞医药 | 95.59% | 行业排名> |